alexa Effects of resistance exercise and creatine supplementation on myasthenia gravis: a case study.


International Journal of Neurorehabilitation

Author(s): Stout JR, Eckerson JM, May E, Coulter C, BradleyPopovich GE

Abstract Share this page

Abstract PURPOSE: The purpose of this case study was to determine the effects of 15 wk of resistance exercise and creatine (Cr) supplementation on body composition, training volume, peak strength, and complete blood chemistry in a patient with myasthenia gravis (MG). METHODS: The patient was a 26-yr-old man who was taking prednisone and azathioprine for his condition. The patient self-administered 5 g of Cr per day in addition to resistance exercise 3 times per week. Fasting blood samples were obtained and body weight (BW) and fat free mass (FFM; via hydrostatic weighing) were measured before and after training and Cr supplementation. In addition, isokinetic (Cybex II) peak strength for leg extension (LE), leg flexion (LF), and volume load (repetition x mass lifted) for the first and last resistance training session were determined. RESULTS: After Cr supplementation and training, the results demonstrated increases in BW (6.8\%), FFM (4.3\%), upper body volume load (37.0\%), lower body volume load (15.0\%), and peak strength for LE (37.0\%) and LF (12.5\%). Moreover, blood chemistry values remained within normal limits for the duration of the 15-wk study. CONCLUSION: These data suggest that resistance exercise plus Cr supplementation may promote gains in strength and FFM in patients with MG.
This article was published in Med Sci Sports Exerc and referenced in International Journal of Neurorehabilitation

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version